3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
8 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
17 citations
,
July 1995 in “International Journal of Dermatology” Minoxidil helps prevent hair loss from chemotherapy in rats.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
April 2016 in “Journal of The American Academy of Dermatology” Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.
2 citations
,
January 2025 in “JAAD Case Reports” Topical metformin may improve hair regrowth in CCCA when added to standard treatments.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
7 citations
,
July 2019 in “Asian Journal of Oncology” Guduchi and Yashtimadhu can reduce chemotherapy side effects.
October 2025 in “Journal of the Endocrine Society” Careful dosing and monitoring are crucial to prevent adrenal insufficiency when using ketoconazole for Cushing's disease.
August 2020 in “International Journal of Medical Arts (Print)” Topical cetirizine helps treat male hair loss.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
20 citations
,
August 2023 in “Saudi Pharmaceutical Journal” Niosomes can effectively deliver cetirizine topically for treating alopecia.
1 citations
,
May 2025 in “Cytotechnology” 4 citations
,
October 2019 in “Skin Appendage Disorders” Gefitinib can cause hair and eyebrow darkening.
April 2024 in “Histochemistry and cell biology” N-acetylcysteine may prevent hair loss caused by chemotherapy.
91 citations
,
April 2006 in “PubMed” EGFR-targeting cancer drugs can cause skin rashes and other side effects.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
Certain antiparasitics and antidepressants show promise for treating cryptococcosis, especially when combined with fluconazole.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
3 citations
,
July 2022 in “Problemy èndokrinologii” Metformin, a diabetes drug, may also help fight cancer, but more research is needed to understand how.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.